3 Things to Watch at Eli Lilly


Eli Lilly gave its presentation at the JPMorgan conference on health care last week, and in this video, Motley Fool health care bureau chief Brenton Flynn gives us three important takeaways for Eli Lilly investors. He tells us to look out for a huge amount of data from the company on testing of some of the drugs in its pipeline in both the diabetes and oncology spaces, and discusses the possibility that the company may seek approval outside of the U.S. for its Alzheimer's candidate drug. He goes on to highlight the company's strong balance sheet and the possibility of a merger or acquisition somewhere down the road.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. Make sure you start 2013 with a bang and get the inside scoop on what Motley Fool Superinvestor David Gardner will be buying this year. He's crushed the market in his Stock Advisor and Rule Breakers portfolios for years, and now I invite you to a personal tour of his flagship stock picking service: Supernova. Just click here now for instant access.

The article 3 Things to Watch at Eli Lilly originally appeared on Fool.com.

Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.